Shares of Baxter International Inc (NYSE:BAX) ended Friday session in green amid volatile trading. The shares closed up +0.21 points or 0.45% at $47.28 with 14,5569,77 shares getting traded. Post opening the session at $47.09, the shares hit an intraday low of $46.75 and an intraday high of $47.40 and the price vacillated in this range throughout the day. The company has a market cap of $25.83 billion and the numbers of outstanding shares have been calculated to be 543.89 million shares.
On August 25, 2016 Baxter International Inc. (BAX), a global leader in renal care, and Satellite Healthcare, a leading, national not-for-profit and the sixth largest provider of patient-centered dialysis and kidney disease services in the U.S., announced an agreement to provide patients with the latest advancements in peritoneal dialysis, hemodialysis and continuous renal replacement therapy.
Under the four-year agreement, Satellite Healthcare plans to offer AMIA Automated Peritoneal Dialysis (APD) system with SHARESOURCE to peritoneal dialysis (PD) patients, and integrate REVACLEAR into its high-flux hemodialysis therapy offering at its 80 Satellite Dialysis and Satellite WellBound home dialysis centers that serve more than 7,000 patients nationwide. Details of the agreement were not disclosed.
”Baxter and Satellite Healthcare share a common goal to provide patients with a better dialysis experience,” said Giuseppe Accogli, corporate vice president and president, Baxter Renal. ”We are pleased to continue our relationship with an organization that is clearly leading the way and revolutionizing how kidney disease patients are cared for in the U.S.”
Satellite Healthcare launched Re-Imagine Home, a long-term initiative to change the landscape of home dialysis with the design of an industry-leading home dialysis model. The aspirational goal through Re-Imagine Home is to double Satellite Healthcare’s home dialysis usage from 20% to 40% of its patient population and increase awareness of home dialysis.
”Our mission is to make life better for our kidney disease patients by offering a personalized care experience that is unlike any other,” said Satellite Healthcare CEO Rick Barnett. ”AMIA, Baxter’s new technology, is a foundational tool for Satellite Healthcare in reaching our Re-Imagine Home goal to make home dialysis an accessible and effective modality option for more dialysis patients.”
Shares of Boston Scientific Corporation (NYSE:BSX) ended Friday session in red amid volatile trading. The shares closed down -0.12 points or -0.51% at $23.50 with 13,251,776 shares getting traded. Post opening the session at $23.57, the shares hit an intraday low of $23.38 and an intraday high of $23.68 and the price vacillated in this range throughout the day. The company has a market cap of $31.82 billion and the numbers of outstanding shares have been calculated to be 1.36 billion shares.
Boston Scientific Corporation (BSX) on Aug. 9, 2016 received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted EMBLEM S-ICD Systems. The new EMBLEM MRI S-ICD System is the latest addition to the company’s growing line of ImageReady™ MR-conditional devices, which allow patients to undergo magnetic resonance imaging (MRI) safely.
The EMBLEM S-ICD System is a proven treatment option for patients at risk of sudden cardiac arrest, that leaves the heart and vasculature untouched, thus reducing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillator leads.
“Now with FDA approval, patients receiving the EMBLEM MRI S-ICD System, as well as patients who previously were implanted with an EMBLEM S-ICD System, have reassurance they can safely undergo MR scans while remaining protected from cardiac arrest,” said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific.